(Q44086086)

29 November 2017

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma (English)

1 reference

29 November 2017

5

Margaret A Shipp

1 reference

29 November 2017

Thomas S Lin

1

1 reference

29 November 2017

Orion M Howard

series ordinal

2

1 reference

29 November 2017

Donna S Neuberg

series ordinal

3

1 reference

29 November 2017

Helen H Kim

series ordinal

4

1 reference

29 November 2017

1 April 2002

1 reference

29 November 2017

1 reference

29 November 2017

43

1 reference

29 November 2017

4

1 reference

29 November 2017

793-797

1 reference

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

29 November 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Mantle-cell lymphoma: a population-based clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Patterns of survival in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190290016908

10.1080/10428190290016908

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference